文献速递肝病消化道肿瘤与早癌

用药不依从增加恩替卡韦治疗的慢性乙型肝炎患者的肝细胞癌、肝硬化并发症和死亡率

Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir.
PubMed 文献 · Am J Gastroenterol · 2018-06-08

这项为期10年的纵向观察性研究纳入894例接受恩替卡韦治疗的初治慢性乙型肝炎患者,总体平均依从率为89.1%。依从性差(<90%)与病毒学突破、肝相关或全因死亡、肝细胞癌及肝硬化并发症风险升高相关,且在肝硬化患者中更为明显。

要点

  • 依从性差(<90%)患者病毒学突破风险显著高于依从性良好者(HR 22.42)。
  • 依从性差与肝相关死亡(HR 14.29)、全因死亡(HR 4.96)、肝细胞癌(HR 2.86)及肝硬化并发症(HR 2.86)风险升高相关。
  • 依从率越低,肝脏相关事件风险进行性升高,肝硬化患者中不利影响更明显。

核心结论

  • 用药依从性差与更高的死亡风险及更高的肝细胞癌和肝硬化并发症风险相关,尤其在肝硬化患者中。

研究设计与样本

  • 为期10年的纵向观察性研究,纳入894例接受恩替卡韦治疗的初治慢性乙型肝炎患者。

主要发现

  • 总体平均依从率为89.1%。
  • 依从性差患者病毒学突破风险高于依从性良好者(HR 22.42;95% CI 19.57-52.52;P < 0.001)。
  • 多因素分析显示依从性差与肝相关死亡(HR 14.29;95% CI 3.49-58.47;P < 0.001)和全因死亡(HR 4.96;95% CI 2.19-11.27;P < 0.001)风险升高相关。
  • 依从性差与肝细胞癌(HR 2.86;95% CI 1.76-4.64;P < 0.001)和肝硬化并发症(HR 2.86;95% CI 1.93-4.25;P < 0.001)风险升高相关。
  • 按依从率<70%、≥70至<90%、≥90%分层后,剂量反应分析显示依从率下降时肝脏相关事件风险进行性升高,肝硬化患者中不利影响更明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Optimal adherence to nucleoside analogue treatment is necessary to achieve undetectable levels of hepatitis B virus (HBV) DNA in patients with chronic hepatitis B (CHB), and to prevent cirrhotic complications. However, any large long-term follow-up study has not been investigated the effect of adherence to entecavir (ETV) treatment on specific liver-related events (LREs), namely, hepatocellular carcinoma (HCC), cirrhotic complications, and mortality. METHODS: This was a 10-year longitudinal observational study of treatment-naïve patients with CHB who received ETV treatment. The primary outcome was the cumulative probability of LREs. The cumulative level of adherence to medication was categorized as good (≥90%) or poor (<90%). RESULTS: Data from 894 treatment-naïve CHB patients who received ETV were analyzed. Overall mean adherence rates were 89.1%. Patients with poor adherence had a higher risk of virologic breakthrough (VBT) (HR, 22.42; 95% CI, 19.57-52.52; P < 0.001) than those with good adherence. Multivariate analyses showed a higher risk of liver-related (HR, 14.29; 95% CI, 3.49-58.47; P < 0.001) or all-cause (HR, 4.96; 95% CI, 2.19-11.27; P < 0.001) mortality, HCC (HR, 2.86; 95% CI, 1.76-4.64; P < 0.001), and cirrhotic complications (HR, 2.86; 95% CI, 1.93-4.25; P < 0.001) with poor adherence. Medication adherence was further stratified into three groups according to adherence rates of <70%, ≥70 to <90%, and ≥90%. The dose-response analyses of adherence rates showed that the risk of LREs increased progressively as medication adherence declined. In particular, the unfavorable effects of nonadherence were more pronounced in patients with cirrhosis. CONCLUSIONS: Poor adherence to medication was associated with a higher mortality and greater risk of HCC and cirrhotic complications, particularly among patients with liver cirrhosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shin JW, Jung SW, Lee SB, et al. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. Am J Gastroenterol. 2018. PMID: 29880971. doi:10.1038/s41395-018-0093-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。